Phathom Pharmaceuticals Inc(PHAT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.27 | Insider Own | 36.68% | Shs Outstand | 80.1M | Perf Week | -18.06% |
| Market Cap | 0.48B | Forward P/E | 8.36 | EPS next Y | 199.43% | Insider Trans | - | Shs Float | 51.2M | Perf Month | -18.5% |
| Enterprise Value | 0.85B | PEG | - | EPS next Q | -0.11 | Inst Own | 60.01% | Short Float | 19.1% | Perf Quarter | -48.54% |
| Income | -0.10B | P/S | 2.02 | EPS this Y | 76.2% | Inst Trans | 7.29% | Short Ratio | 6.68 | Perf Half Y | -47.13% |
| Sales | 0.24B | P/B | - | EPS next 5Y | - | ROA | -34.32% | Short Interest | 9.78M | Perf YTD | -63.89% |
| Book/sh | -4.3 | P/C | 2.66 | EPS past 3/5Y | 15.64% 4.82% | ROE | - | 52W High | -67.29% ($18.31) | Perf Year | -56.63% |
| Cash/sh | 2.26 | P/FCF | - | Sales past 3/5Y | - | ROIC | -58.35% | 52W Low | 19.44% ($5.01) | Perf 3Y | -30.83% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 73.04% | Gross Margin | 82.92% | Volatility(W/M) | 11.56% 7.07% | Perf 5Y | -75.81% |
| Dividend TTM | - | EV/Sales | 3.56 | Sales Y/Y TTM | 110.16% | Oper. Margin | -16.96% | ATR (14) | 0.51 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.87 | EPS Q/Q | 79.93% | Profit Margin | -41.34% | RSI (14) | 33.95 | Recom | 1.45 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.92 | Sales Q/Q | 88.02% | SMA20 | -13.16% ($6.9) | Beta | 0.67 | Target Price | $19.64 |
| Payout | - | Debt/Eq | - | Earnings | 2026/10/29 | SMA50 | -23.4% ($7.82) | Rel Volume | 1.44 | Prev Close | $5.94 |
| Employees | 371 | LT Debt/Eq | - | EPS/Sales Surpr. | -19.59% 1.42% | SMA200 | -43.36% ($10.58) | Avg Volume(3M) | 1.46M | Price | $5.99 |
| IPO | 2019/10/25 | Option/Short | Yes/Yes | Trades | 10312 | Volume | 2,104,022 | Change | 0.84% |
💊 Phathom Pharmaceuticals (PHAT) is a U.S. biopharmaceutical company focused on therapies for gastrointestinal diseases. Its core asset is vonoprazan, a potassium-competitive acid blocker (PCAB), which is marketed in the United States under the brand name VOQUEZNA for the treatment of erosive and non-erosive gastroesophageal reflux disease (GERD) and Helicobacter pylori infections. Leveraging a mechanism of action that differentiates it from traditional proton pump inhibitors (PPIs), the company is delivering rapid revenue growth in the early stages of commercialization.
Over the past 1 year, on the lower side
67% below its 1-year high.
Traded more than usual. That is 144% of its average volume.
Next earnings report: October 29
1 days to go.
PHAT has a sound balance sheet but weak earning power
Of every $100 in sales, $16.96 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +76.2% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $202. Peers typically go for $1,261. Compared with its own 1-year average, it is 73% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -75.8%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 60.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #221 of 594 in the industry
Based on market cap of $485M.
CBIO#219 Crescent Biopharma Inc $493M PER - 
ARVN#220 Arvinas Inc $487M PER 46.5 PHAT#221 Phathom Pharmaceuticals Inc $485M PER - 
OCS#222 Oculis Holding AG $483M PER - 
MNPR#223 Monopar Therapeutics Inc $482M PER - 
FAQ
What kind of company is PHAT?
PHAT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PHAT?
The market cap of PHAT is approximately $485M, ranking 3,185 within its sector.
What is the 52-week high and low for PHAT?
PHAT has recorded a 52-week high of $18.31 and a low of $5.01.
